alpha-synuclein inhibitors, kinase inhibitors & targeting mitochondria in parkinson’s disease
Published 2 years ago • 491 plays • Length 2:05Download video MP4
Download video MP3
Similar videos
-
1:54
targeting α-synuclein as a therapy for parkinson’s disease: strategies in the pipeline
-
4:31
is α-synuclein a useful therapeutic target in parkinson's disease?
-
1:26
targeting α-synuclein & neuroinflammation in parkinson's disease
-
2:26
alpha-synuclein as a therapeutic target for parkinson's disease
-
1:46
therapeutic approaches to target alpha-synuclein in parkinson’s disease
-
1:21
investigating α-synuclein aggregation as a therapeutic target in parkinson’s disease
-
1:57
alpha-synuclein pathology: dangerous mitochondrial interactions
-
1:34
is α-synuclein aggregation a cause or consequence of parkinson’s disease?
-
1:29
prasinezumab: an anti-alpha-synuclein antibody in parkinson's disease
-
1:00
parkinson’s disease, alpha synuclein, a practical explanation
-
4:00
peripheral α-synuclein as a parkinson’s disease biomarker
-
2:43
doxycycline inhibits alpha-synuclein aggregation in pd models
-
2:02
glycation of α-synuclein in parkinson’s disease
-
3:24
key mechanisms in parkinson’s disease: mitochondrial dysfunction, lipids, & lysosomal dysfunction
-
2:49
is clearing α-synuclein enough to treat parkinson’s disease?
-
1:01
alpha-synuclein and parkinson’s disease
-
2:47
α-synuclein & parkinson's disease: moving away from anti-α-synuclein approaches?
-
1:02
α-synuclein seed amplification assay for diagnosing parkinson's disease
-
2:19
advances in alpha-synuclein as a biomarker for parkinson's disease